Comment from Avedro, Inc.

Summary: Avedro, Inc., a pharmaceutical and medical device company, opposes the inclusion of Ophthalmic Riboflavin on the FDA's 503B Bulks List. They argue that there is no clinical need for compounded riboflavin because Avedro's own products are the only FDA-approved solutions for treating progressive keratoconus and that the nomination lacks adequate supporting data.